Effect of Statins on the Progression of Coronary Calcification in Kidney Transplant Recipients

Página do item simplificado
dc.citation.issue4
dc.citation.volume11
dc.contributor.authorYazbek, Daniel Constantino [UNIFESP]
dc.contributor.authorCarvalho, Aluizio Barbosa de [UNIFESP]
dc.contributor.authorBarros, Cinara Sa [UNIFESP]
dc.contributor.authorPestana, Jose Osmar Medina [UNIFESP]
dc.contributor.authorCanziani, Maria Eugenia Fernandes [UNIFESP]
dc.coverageSan Francisco
dc.date.accessioned2020-07-22T13:23:07Z
dc.date.available2020-07-22T13:23:07Z
dc.date.issued2016
dc.description.abstractBackground Coronary calcification (CAC) is highly prevalent in kidney transplant recipients (KTRs) and has been associated with cardiovascular morbidity and mortality. Some studies have shown a reduction in CAC progression with statin therapy in the general and chronic kidney disease (CKD) populations. Objectives and Methods The aim of the present study was to evaluate the effect of statins on CAC progression in incident kidney transplant recipients. Patients were randomly assigned to the statin (n = 61, 10 mg daily) and control group (n = 59). CAC and biochemical analyses were performed at baseline and 12 months. Results At baseline, CAC was observed in 30% and 21% of patients in the statin and control groups, respectively (p = 0.39). The calcium score at baseline and its absolute and relative changes over 12 months of follow up were similar among the groups. In the statin group, total cholesterol (p < 0.001), low density lipoprotein cholesterol (p < 0.001) and triglycerides (p = 0.005) decreased, and the estimated glomerular function rate increased (p < 0.001) significantly. CRP levels remained stable (p = 0.52) in the statin group but increased in the control group (p = 0.01). In the multivariate model, there was no difference in CAC progression between the groups (group effect p = 0.034en
dc.description.abstracttime-effect p = 0.23en
dc.description.abstractinteraction p = 0.74). Similar results were obtained when only patients with >= 10AU calcium score (calcified) were analyzed (group effect p = 0.051en
dc.description.abstracttime-effect p = 0.58en
dc.description.abstractinteraction p = 0.99). Conclusion Although statins reduce the levels of cholesterol, triglycerides, inflammation and improve graft function, the dose adopted in the current study did not delay CAC progression within 12 months of follow up.en
dc.description.affiliationUniv Fed Sao Paulo, Div Nephrol, Sao Paulo, SP, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo, Div Nephrol, Sao Paulo, SP, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipFundacao de amparo a pesquisa do estado de Sao Paulo (FAPESP)
dc.format.extent-
dc.identifierhttp://dx.doi.org/10.1371/journal.pone.0151797
dc.identifier.citationPlos One. San Francisco, v. 11, n. 4, p. -, 2016.
dc.identifier.doi10.1371/journal.pone.0151797
dc.identifier.fileWOS000374898500007.pdf
dc.identifier.issn1932-6203
dc.identifier.urihttps://repositorio.unifesp.br/handle/11600/56045
dc.identifier.wosWOS:000374898500007
dc.language.isoeng
dc.publisherPublic Library Science
dc.relation.ispartofPlos One
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleEffect of Statins on the Progression of Coronary Calcification in Kidney Transplant Recipientsen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Artigos